Spelman, T. Et Al. 2018. Comparative effectiveness of switching to natalizumab or fingolimod after relapse on first-line relapsing-remitting multiple sclerosis therapy: propensity score matching analysis from the MSBase registry.. 34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) , (Berlin, Germany), 25-26.

Spelman, T., Harvrdova, E. K., Horakova, D., Izquierdo, G., Kalincik, T., Lugaresi, A., ... Onofrj, M.(2018). Comparative effectiveness of switching to natalizumab or fingolimod after relapse on first-line relapsing-remitting multiple sclerosis therapy: propensity score matching analysis from the MSBase registry. . 34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) (pp.25-26). Berlin, Germany

Spelman, T. Et Al. "Comparative effectiveness of switching to natalizumab or fingolimod after relapse on first-line relapsing-remitting multiple sclerosis therapy: propensity score matching analysis from the MSBase registry.," 34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Berlin, Germany, 2018

Spelman, T. Et Al. "Comparative effectiveness of switching to natalizumab or fingolimod after relapse on first-line relapsing-remitting multiple sclerosis therapy: propensity score matching analysis from the MSBase registry.." 34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) , Berlin, Germany, pp.25-26, 2018

Spelman, T. Et Al. (2018) . "Comparative effectiveness of switching to natalizumab or fingolimod after relapse on first-line relapsing-remitting multiple sclerosis therapy: propensity score matching analysis from the MSBase registry.." 34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) , Berlin, Germany, pp.25-26.

@conferencepaper{conferencepaper, author={T. Spelman Et Al. }, title={Comparative effectiveness of switching to natalizumab or fingolimod after relapse on first-line relapsing-remitting multiple sclerosis therapy: propensity score matching analysis from the MSBase registry.}, congress name={34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)}, city={Berlin}, country={Germany}, year={2018}, pages={25-26} }